StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 4.5
Power Rank trend -> Falling
07/26/2024 16:23:00 EST
Tandem Diabetes Care Inc (TNDM)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, TNDM has been trading in a range between $47.30 and $39.15 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
Upside / Downside Potential
Tandem Diabetes Care Inc $TNDM entered a Red zone 3 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $39.33, a potential down side of -1.8% from the recent price of 40.05. The stock is trading 34.06% (potential upside) below its 52 week high of $53.69 and 189.8 % (potential downside) above its 52 week low of $13.82 - based on the recent price.
Company Summary
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
News
| Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024 SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diab. Source: Business Wire Thu, 11 Jul 2024 16:05:00 -0400 Sentiment: Neutral |
| Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi Tandem Diabetes Care, Inc. TNDM announced the latest real-world insights from a user satisfaction survey on their Tandem Mobi system during the 84th Scientific Sessions of the American Diabetes Association (“ADA”) in Orlando, FL. Data from the survey demonstrated that Tandem Mobi helps improve the quality of life for patients with type 1 diabetes. Source: Zacks Investment Research Tue, 02 Jul 2024 05:10:31 -0400 Sentiment: Positive |
| Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions. Source: Business Wire Sat, 22 Jun 2024 11:00:00 -0400 Sentiment: Neutral |
| Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude “JC” Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. “JC brings deep experience in healthcare and a great balance of tech. Source: Business Wire Thu, 20 Jun 2024 09:00:00 -0400 Sentiment: Neutral |
| The 3 Best Diabetes Stocks to Buy in June 2024 Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That's because Dexcom (NASDAQ: DXCM ) delivered stronger-than-expected third-quarter results in October. Source: InvestorPlace Wed, 19 Jun 2024 06:02:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 53.69 52 Week Low: 13.82 Beta: 1.287 50 Day MA: 45.6382 200 Day MA: 31.2187 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.37 Qtr Revenue Growth YOY: 0.132 Forward PE: 1111.1111 Trailing PE: 0